Cancer

Mouse studies suggest combined inhibition of EGFR and β-catenin could help treat EGFR-mutant NSCLC. In two xenograft mouse models of EGFR-mutant NSCLC, the EGFR inhibitor Tarceva erlotinib and a tool compound β-catenin inhibitor decreased tumor growth and recurrence and increased overall survival compared with either agent alone. Next steps could include testing combinations of other EGFR and β-catenin inhibitors in models of EGFR-mutant NSCLC.

Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Roche and its Genentech Inc. unit market Tarceva to treat NSCLC, brain and pancreatic cancer...